Condition: Retinitis Pigmentosa (RP) · Usher Syndrome · Cone Rod Dystrophy · Sponsor: Okuvision GmbH
Retinitis pigmentosa and similar degenerative diseases of the retina lead to progressive loss of vision. TES therapy with the CE-marked OkuStim® System is a treatment approved in the EU for slowing the progression of the disease. Patients increasingly report short-term subjective improvements in vision, which have not yet been systematically investigated. This exploratory study is conducted to determine whether these subjective short-term effects can be measured, and therefore also be quantified, by objective tests.
This description comes directly from the study's public registry record.
Claudia Büdel · +49 69 7566 8880 · info@azffm.de
Always discuss trial participation with your own doctor first.
| Augenzentrum Frankfurt Prof. Koch GmbH | Frankfurt am Main, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07548944